On April 8, 2020, the European Commission (“Commission”) published a communication containing a temporary framework for assessing antitrust issues related to business cooperation in response to situations of urgency stemming from the current COVID-19 outbreak (“European Communication”). At the same time, the Commission issued its first written comfort letter to an association of manufacturers of generic and non-generic medicines (Medicines for Europe) on the compatibility of a specific cooperation project that targets the risk of shortage of essential medicines for hospital use with the prohibition on anti-competitive agreements (Article 101 TFEU [1]). At national level, on April 22, 2020, the Italian Competition Authority (Autorità Garante della Concorrenza e del Mercato, or “AGCM”)
Share on
|
|
The EU Commission publishes its communication containing a temporary framework for assessing antitrust issues related to business cooperation in response to the COVID-19 pandemic
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
